GPR35 has long been considered an orphan GPCR, because no endogenous ligand of GPR35 has been discovered. CXCL17 (a chemokine) has been reported to be an endogenous ligand of GPR35, and it has even been suggested that it be called CXCR8. However, at present there is no supporting evidence that CXCL17 does interact with GPR35.
Introduction
Human GPR35 was first described as an intronless GPCR gene encoding 309 amino acids (O'Dowd et al., 1998) , and subsequently, it was reported to be expressed in lungs, stomach, small intestine, colon, spleen and immune cells (including mast cells, basophils, eosinophils and invariant natural killer-like T cells) in man (Wang et al., 2006; Fallarini et al., 2010; Yang et al., 2010) . For a considerable time, GPR35 was considered an orphan receptor as no endogenous ligand had been discovered. Several endogenous molecules, such as lysophosphatidic acid, kynurenic acid, cGMP and reverse T3, were proposed as ligands (Wang et al., 2006; Oka et al., 2010; Jenkins et al., 2011; Deng et al., 2012; Southern et al., 2013) , but their potencies were too low (in the μM range) to support their roles as GPR35 ligands (Divorty et al., 2015) . Synthetic surrogate agonists, such as zaprinast, pamoic acid, compound 1, PSB-13253 and lodoxamide, have been successfully identified or developed (Taniguchi et al., 2006; Jenkins et al., 2010; Zhao et al., 2010; Funke et al., 2013; Neetoo-Isseljee et al., 2013; Thimm et al., 2013; MacKenzie et al., 2014) , and of these lodoxamide most potently interacts with human and rodent GPR35 (MacKenzie et al., 2014) . Selective synthetic antagonists for GPR35 were also developed, that is, CID-2745687 (also known as SPB05142 and ML194) and CID-2786812 (ML145) (Zhao et al., 2010; Heynen-Genel et al., 2010a,b; Jenkins et al., 2012) . GPR35 has been reported to couple to both Gα i/o and Gα 13 subunits and to recruit β-arrestin-2 (Wang et al., 2006; Guo et al., 2008; Ohshiro et al., 2008; Jenkins et al., 2010 Jenkins et al., , 2011 . Recently, CXCL17 (a chemokine) was reported to be an endogenous ligand of GPR35, and GPR35 was proposed to be CXCR8 (Maravillas-Montero et al., 2015) . Furthermore, it was reported that CXCL17 increases the intracellular Ca 2+ concentration in THP-1 cells (a human monocytic cell line) to promote chemotaxis at a concentration of 100 nM (Maravillas-Montero et al., 2015) . However, no supporting evidence has since been obtained with respect to the relationship between CXCL17 and GPR35, despite the fact that GPR35 is an emerging target in several pathological conditions, including inflammatory and cardiovascular diseases (Divorty et al., 2015) . The results presented by MaravillasMontero et al. (2015) are intriguing but conflict with previous findings (Divorty et al., 2015) . Accordingly, verification of this ligand-receptor interaction by another laboratory or using another assay system is required (Im, 2004) . Therefore, we used two assay systems to verify the matching of CXCL17 and GPR35. An AP-TGF-α shedding assay in GPR35 overexpressing HEK293 cells was used as a gain-of-function assay, and a GPR35 knock-down system, obtained by siRNA transfection, was applied to endogenously GPR35-expressing THP-1 cells as a loss-of-function assay. 
Methods

AP-TGF-α shedding assay
Migration assay
THP-1 migration was measured using 24-well Transwell inserts (6.5 mm) fitted with polycarbonate filters (5 μm pore size) (Corning Costar, Acton, MA, USA). THP-1 cells (1 × 10 6 cells in 150 μL of RPMI 1640 medium) were added to the upper chamber, and 600 μL of RPMI 1640 medium containing the indicated concentrations of lodoxamide or human CXCL17 was added to the lower chamber. Plates were incubated at 37°C in 5% CO 2 for 24 h, and the cells that migrated into the lower chamber were collected and counted using a haemocytometer.
Transfection
The following oligonucleotides were purchased from Bioneer (Korea); GPR35 siRNA sense 5
0 . SN-1003 from Bioneer was used as scrambled siRNA. Briefly, THP-1 cells were seeded at a density of 1.0 × 10 5 cells in 12 well plates, and 24 h later, GPR35 siRNA (100 nM) was introduced to the cells using Lipofectamine LTX reagent (Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. Non-silencing siRNA and siRNAs specific for GPR35 were transfected, and 48 h after transfection, target knock-downs were confirmed by RT-PCR and Western blotting.
Statistics
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Results are expressed as the means ± SEM for the number of determinations indicated. The statistical significances of differences were determined by ANOVA, and significance was accepted for P values <0.01. * Indicates significance compared to untreated controls and # compared to lodoxamide-treated or negative control groups.
Materials
Lodoxamide was purchased from Toronto Research Chemicals Inc. (North York, ON, Canada), and kynurenic acid was from Sigma-Aldrich (St. Louis, MO, USA). Recombinant mouse CXCL17 and human CXCL17 were purchased from R&D system (Minneapolis, MN, USA), and zaprinast, CID-2745687 and pamoic acid were from Tocris (Ellisville, Missouri, USA). Plasmids for the AP-TGF-α shedding assay, that is, an alkaline phosphatase fusion protein of TGF-α, human GPR35 and eight Gα proteins, were kindly provided by Dr Junken Aoki at Tohoku University. The antibody for GPR35 (NBP2-24640) was purchased from Novus Biologicals (Littleton, CO, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 (Alexander et al., 2017) .
Results
Lodoxamide, but not CXCL17, activates GPR35 in HEK293 cells
As a gain-of-function assay, GPR35 was overexpressed in HEK293 cells and its activity was measured by AP-TGF-α shedding assay. AP-TGF-α shedding assay is generally considered the best system to test or verify functions of almost all GPCRs (Inoue et al., 2012) . Lodoxamide (a synthetic GPR35 agonist) was found to be a more potent agonist than other reported agonists, such as pamoic acid, kynurenic acid and zaprinast ( Figure 1A ). EC 50 values for lodoxamide, pamoic acid, zaprinast and kynurenic acid were 1 nM, 9 nM, 0.7 μM and 4.1 mM respectively. Furthermore, the lodoxamide-induced activation of GPR35 was concentration-dependently inhibited by CID2745687 (a selective GPR35 antagonist) ( Figure 1B ). AP-TGF-α shedding was observed when GPR35 was co-transfected with Gα q/i1 , Gα q/i3 , Gα q/o , Gα q/12 or Gα q/13 , but not with Gα q/s , Gα q/z or Gα 16 (Figure 2 ), which suggests GPR35 can couple to Gα i1 , Gα i3 , Gα o , Gα 12 or Gα 13 , which is consistent with the previously reported G protein coupling character of GPR35 to Gα i/o and Gα 13 (Divorty et al., 2015) . However, neither human nor mouse CXCL17 activated GPR35 (Figure 3 ), which contrasts with the previous report by Maravillas-Montero et al. (2015) .
Lodoxamide inhibits the migration of THP-1 cells through GPR35, but CXCL17-stimulated migration is not dependent on GPR35
THP-1 cells were used for the loss-of-function assay, because they express GPR35 endogenously and because its involvement in the action of CXCL17 action was observed only in these cells (Maravillas-Montero et al., 2015) . We observed that CXCL17 stimulated the migration of THP-1 cells ( Figure 4A ), which is consistent with the previous findings (Maravillas -Montero et al., 2015) . However, the CXCL17-induced simulation of migration was not blocked by treatment with the GPR35 antagonist CID2745687 ( Figure 4B ) or by GPR35 siRNA transfection ( Figure 5C ). In contrast, lodoxamide inhibited the migration of THP-1 cells in a concentration-dependent manner ( Figure 4C ), and this inhibition by lodoxamide was blocked by CID2745687 treatment ( Figure 4D ) or GPR35 siRNA transfection ( Figure 5D ). These findings suggest that GPR35 functions as a migration inhibitory receptor for lodoxamide in THP-1 cells and that CXCL17 stimulates migration in a GPR35-independent manner.
Discussion
Confirmation of ligand-receptor matching by another laboratory is important, because mismatching can cause considerable confusion, as exemplified by the mismatching of OGR-1 and GPR4 with sphingosylphosphorylcholine and lysophosphatidylcholine respectively (Xu and Casey, 1996; Zhu et al., 2001 Zhu et al., , 2005 Bektas et al., 2003) . However, when several assay systems support a ligand-receptor matching result, even in a single report, the result is usually reliable, for example, for the LPA-GPR23 interaction (GPR23 was later renamed as the LPA 4 receptor) (Noguchi et al., 2003; Im, 2004; Lee et al., 2007; Kihara et al., 2014) . In the case of CXCL17-GPR35 matching, MaravillasMontero et al. reported that CXCL17 promotes the chemotaxis of THP-1 cells in a pertussis toxin-sensitive manner and that chemotaxis was enhanced in PGE 2 -treated THP-1 cells (Maravillas-Montero et al., 2015) . These findings support the notion that CXCL17 can induce chemotaxis and that its receptor might be coupled to pertussis toxin-sensitive Gα i/o proteins (Maravillas-Montero et al., 2015) . Our data support the stimulatory effect of CXCL-17 on migration in THP-1 cells. However, GPR35 was not found to be involved. Increased expression of GPR35 in PGE 2 -treated THP-1 cells and reduced expression of GPR35 in the lungs of CXCL17 knockout mice were suggested to be indirect evidence of CXCL17-GPR35 matching (Maravillas-Montero et al., 2015), but these increased or decreased expression levels of GPR35 might have occurred coincidentally due to variable responses to CXCL17 (Maravillas-Montero et al., 2015) . Maravillas-Montero et al. also reported that CXCL17 increases the intracellular Ca 2+ concentration in human THP-1 cells (Maravillas-Montero et al., 2015) . Furthermore, CXCL17-induced intracellular Ca 2+ increase was observed in GPR35-transfected BA/F3 cells and HEK293 cells (MaravillasMontero et al., 2015) . However, these cells were not treated with a GPR35 antagonist or subjected to GPR35 knock-down to confirm that GPR35 mediated this CXCL17-induced Ca (Jenkins et al., 2011; Mackenzie et al., 2011; Maravillas-Montero et al., 2015) . Similarly, it was reported that lysophosphatidic acid induced and increase in Ca 2+ in GPR35-expressing HEK293 cells (Oka et al., 2010) , although this was contradicted by subsequent reports (Oka et al., 2010; Southern et al., 2013; Divorty et al., 2015) . In addition, we did not observe a CXCL17-induced increase in intracellular Ca 2+ in THP-1 cells, although we did observe that ATP increased Ca 2+ in these cells (Supporting Information Figure S1 ). As mentioned above, pharmacological evidence for CXCL17-GPR35 matching was inadequate in the previous study and was not supported by our findings. To summarize, CXCL17 did not activate GPR35 in the AP-TGF-α shedding assay, which provided a means of validating the effects of other GPR35 activators. Furthermore, CXCL17-promoted migration was not blocked by CID-2745687 (a GPR35 selective antagonist) or by GPR35 knock-down in THP-1 cells. However, lodoxamide inhibited migration in these THP-1 cells, and this inhibitory effect was blocked by CID-2745687 and by GPR35 knock-down. Therefore, our findings indicate that GPR35 functions as a migration inhibitory receptor and that CXCL17 stimulates migration in a GPR35-independent manner in THP-1 monocytic cells. There are two isoforms of human GPR35, that is, the short GPR35a and long GPR35b (Okumura et al., 2004) . As shown in Supporting Information Figure S2 , GPR35a is mainly expressed in THP-1 cells and we used GPR35a. Because lodoxamide has been used as a mast cell stabilizer, we tested the selectivity of lodoxamide for GPR35 by applying the AP-TGF-α shedding assay in H 1 histamine or LPA 1 lysophosphatidic acid receptor overexpressing HEK293 cells. As shown in Supporting Information Figure S3 , the H 1 and LPA 1 receptors were confirmed to be functional, but lodoxamide did not activate either receptor.
Supporting Information
Additional Supporting Information may be found online in the supporting information tab for this article.
https://doi.org/10.1111/bph.14082 Figure S1 Effects of lodoxamide, CXCL17, and APT on intracellular Ca2 + concentrations in THP-1 cells. A) Representative
[Ca2+]itraces of THP-1 cells treated with lodoxamide(100 nMor 1 mM), hCXCL17 (100 nM), mCXCL17 (100 nM), or ATP (100 mM). Arrows indicate when compounds were added.B) Histogram of Ca2 + responses. Results are presented as the means ± SEs of three independent experiments. Figure S2 THP-1 cells express GPR35a. RT-PCR was conducted to detect GPR35a and GPR35b. THP-1 cells expressed mainly GPR35a and we used GPR35a. Primersequences are followings. hGPR35a Forward GTGTTCGTGGTCTGCTTCC T, hGPR35b Forward GTCCTTGCGTCTCTCTGACC, hGPR35 Reverse GAGAGTCCTGGCTTTTGTGG. 
